Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allogene Therapeutics SEC filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic CAR T product candidates. The filings cover material-event reports, operating and financial updates, common stock registration and offering activity, and clinical disclosures involving programs such as cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease.
Allogene's proxy materials describe annual meeting proposals, shareholder voting matters, board governance, executive compensation, and equity award disclosures. Other filings address Nasdaq-listed common stock, capital-structure changes, material agreements, and risk factors tied to research and development, clinical execution, regulatory matters, intellectual property, and licensed gene-editing technology used in its allogeneic CAR T programs.
Allogene Therapeutics, Inc. shareholder David D. Chang reports beneficial ownership of 12,101,223 shares of common stock, representing 5.2% of the company. This percentage is based on 224,730,144 shares outstanding as of November 4, 2025, as reported in Allogene’s Form 10-Q.
Dr. Chang’s reported holdings include 6,373,347 shares issuable within 60 days of December 31, 2025 upon exercise of stock options, as well as shares held through several California trusts. The Chang 2006 Family Trust holds 1,201,108 shares, and the JEC 2019 Trust and RTC 2019 Trust each hold 856,044 shares, all reported with shared or sole voting and dispositive powers as specified.
Allogene Therapeutics SVP and Chief Technical Officer Benjamin Machinas Beneski reported new equity awards and a small share sale. On February 2, 2026, he sold 7,549 shares of common stock at a weighted average price of $1.73 solely to cover tax withholding on vesting restricted stock units, under a mandatory “sell to cover” arrangement rather than a discretionary trade. He received a stock option for 373,757 shares at $1.87 per share, vesting 25% on February 2, 2027 and the balance in 36 monthly installments. He was also granted 105,720 restricted stock units, each representing one share, vesting in four equal annual installments starting February 2, 2026, subject to continued service. Following these transactions, he directly owned 210,172 shares of common stock.
Allogene Therapeutics President and CEO David D. Chang reported new equity awards and a tax-related share sale. On February 2, 2026, he received a stock option for 1,387,931 shares of common stock at an exercise price of $1.87 per share, vesting 25% on February 2, 2027, with the rest vesting in 36 equal monthly installments. He also received 392,586 restricted stock units, each representing one share of common stock, vesting in four equal annual installments from February 2, 2026, subject to continued service. To cover tax withholding on RSU vesting, 95,269 shares of common stock were sold at a weighted average price of $1.80 in a mandated "sell to cover" transaction, which the filing states was not a discretionary trade. After these transactions, he directly beneficially owned 5,185,862 shares of common stock and additional indirect holdings through several family trusts.
Allogene Therapeutics’ chief financial officer Geoffrey M. Parker reported routine equity compensation activity and a tax-related share sale. On February 2, 2026, he sold 24,001 shares of common stock at a weighted average price of $1.76 solely to cover tax withholding on vesting restricted stock units, under a mandated “sell to cover” arrangement. Following this, he directly owned 1,252,795 common shares. On the same date, he received a stock option to buy 539,072 shares at an exercise price of $1.87 per share, vesting 25% on February 2, 2027 and the rest in 36 monthly installments. He also received 152,480 restricted stock units, each equal to one share of common stock, vesting in four equal annual installments starting February 2, 2026, subject to continued service.
Allogene Therapeutics SVP and General Counsel Douglas Earl Martin reported new equity awards and a related share sale. On February 2, 2026, he was granted a stock option covering 539,072 shares of common stock at an exercise price of $1.87 per share. Twenty‑five percent of this option will vest on February 2, 2027, with the remaining shares vesting in 36 equal monthly installments.
He also received 152,480 restricted stock units, each representing one share of common stock, which will vest in four equal annual installments starting February 2, 2026, subject to continued service. On the same date, he sold 22,900 shares of common stock at a weighted average price of $1.76 to cover tax withholding obligations from RSU vesting, and this was not a discretionary trade. After the sale, he directly beneficially owned 564,948 shares of common stock.
Allogene Therapeutics, Inc. SVP Finance Annie Yoshiyama reported new equity awards and a small tax-related share sale. On February 2, 2026, she received a stock option for 179,691 shares of common stock at an exercise price of $1.87 per share and an award of 50,827 restricted stock units (RSUs). The option vests 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments, while the RSUs vest in four equal annual installments starting from February 2, 2026, subject to continued service. On the same date, she sold 4,167 shares of common stock at a weighted average price of $1.72 solely to cover tax withholding on vesting RSUs, under a mandatory “sell to cover” arrangement, and reported owning 130,322 common shares directly afterward.
Allogene Therapeutics EVP of R&D Zachary Roberts reported equity award grants and a tax-related share sale. On February 2, 2026, he was granted a stock option for 718,763 shares of common stock at an exercise price of $1.87 per share, vesting 25% on February 2, 2027 and the rest in 36 monthly installments. He also received 203,307 restricted stock units, which vest in four equal annual installments starting February 2, 2026, each RSU representing one share. The filing shows a sale of 35,700 common shares at a weighted average price of $1.77 solely to cover tax withholding on RSU vesting under a mandatory “sell to cover” arrangement, leaving him with 581,166 common shares held directly.
Allogene Therapeutics director Arie Belldegrun reported new equity awards and updated share holdings. On February 2, 2026, he was granted a stock option for 929,913 shares of common stock at an exercise price of $1.87 per share and an award of 263,033 restricted stock units (RSUs), both held directly.
Twenty-five percent of the option vests on February 2, 2027, with the balance vesting in 36 equal monthly installments. The RSUs vest in four equal annual installments starting February 2, 2026, subject to continued service. Indirect common stock holdings are reported in entities including Bellco Legacy Trust fbo Rebecka Belldegrun, Vida Ventures LLC, Vida Ventures III partnerships, and Bellco Legacy LLC, along with 2,236,816 common shares held directly.
ALLO had a Form 144 filed to permit the sale of 22,900 shares of its common stock through Morgan Stanley Smith Barney LLC on or about 02/02/2026, to be sold on NASDAQ with an aggregate market value of $40,214.69.
The shares were acquired on 01/31/2026 as restricted stock vesting under a registered compensation plan, with compensation listed as the form of payment. The filing notes that 224,730,144 shares of common stock were outstanding.
A holder of ALLO common stock has filed a Rule 144 notice to sell 24,001 shares through Morgan Stanley Smith Barney LLC on or about 02/02/2026 on NASDAQ. The aggregate market value of the planned sale is listed as $42,188.96, with issuer shares outstanding of 224,730,144.
The shares were acquired as restricted stock vesting under a registered compensation plan from the issuer on 01/31/2026, in a non-cash transaction classified as compensation. The seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.